(2R)-2-amino-6-{N'-[3-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxy-4-methyloxolan-2-yl]methyl}sulfanyl)propyl]carbamimidamido}hexanamide

ID: ALA5266117

Chembl Id: CHEMBL5266117

Max Phase: Preclinical

Molecular Formula: C21H36N10O3S

Molecular Weight: 508.65

Names and Identifiers

Canonical SMILES:  C[C@@H]1[C@H](O)[C@@H](CSCCCNC(=N)NCCCC[C@@H](N)C(N)=O)O[C@H]1n1cnc2c(N)ncnc21

Standard InChI:  InChI=1S/C21H36N10O3S/c1-12-16(32)14(34-20(12)31-11-30-15-17(23)28-10-29-19(15)31)9-35-8-4-7-27-21(25)26-6-3-2-5-13(22)18(24)33/h10-14,16,20,32H,2-9,22H2,1H3,(H2,24,33)(H2,23,28,29)(H3,25,26,27)/t12-,13-,14-,16+,20-/m1/s1

Standard InChI Key:  HWGPUBUWBOCZRP-JWCPYIQLSA-N

Alternative Forms

1. Parent:

   

   ALA5266117

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 508.65

Molecular Weight (Monoisotopic): 508.2693

AlogP: -0.48

#Rotatable Bonds: 13

Polar Surface Area: 216.10

Molecular Species: BASE

HBA: 11

HBD: 7

#RO5 Violations: 3

HBA (Lipinski): 13

HBD (Lipinski): 10

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 13.80

CX Basic pKa: 12.23

CX LogP: -1.26

CX LogD: -4.57

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.10

Np Likeness Score: 0.42

References

1. Fu S, Zheng Q, Zhang D, Lin C, Ouyang L, Zhang J, Chen L..  (2022)  Medicinal chemistry strategies targeting PRMT5 for cancer therapy.,  244  [PMID:36274274] [10.1016/j.ejmech.2022.114842]

Source

Source(1):

• Scientific Literature